{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:33:52Z","timestamp":1787070832489,"version":"build-2736575974"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Drug-induced infiltrative lung disease (DI-ILD) can be caused by chemotherapeutic agents, antibiotics, antiarrhythmic drugs, and immunosuppressive agents. Common chemotherapeutic drugs causing DI-ILD include bleomycin, mitomycin C, bis (2-chloroethyl)-l-nitrosourea, cyclophosphamide, busulfan, and methotrexate. Taxanes and trastuzumab are also associated with lung injury. Estimated incidence of paclitaxel-induced lung injury is 0.73%\u201312%. Although cases of paclitaxel-induced lung injury have been reported previously, we found only one published case report of fatal lung injury caused by paclitaxel use. We are reporting the largest case series of seven patients who developed paclitaxel-induced lung injury along with review of literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1225_16","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T04:18:24Z","timestamp":1556597904000},"page":"262-265","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Drug-induced infiltrative lung disease with weekly paclitaxel in breast cancer"],"prefix":"10.4103","volume":"17","author":[{"given":"Renu","family":"Raghupathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channappa","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravesh","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-44-20241021","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.07-0851","article-title":"Pulmonary complications of novel antineoplastic agents for solid tumors","volume":"133","author":"Vahid","year":"2008","journal-title":"Chest"},{"key":"R2-44-20241021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/ijgc-00009577-200602001-00071","article-title":"Fatal pulmonary fibrosis induced by paclitaxel: A case report and review of the literature","volume":"16","author":"Ostoros","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R3-44-20241021","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000326063","article-title":"Delayed paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer","volume":"4","author":"Abulkhair","year":"2011","journal-title":"Case Rep Oncol"},{"key":"R4-44-20241021","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000011873","article-title":"Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy","volume":"55","author":"Fujimori","year":"1998","journal-title":"Oncology"},{"key":"R5-44-20241021","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2214\/ajr.176.3.1760718","article-title":"Paclitaxel-induced hypersensitivity pneumonitis: Radiographic and CT findings","volume":"176","author":"Wong","year":"2001","journal-title":"AJR Am J Roentgenol"},{"key":"R6-44-20241021","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00001813-199908000-00002","article-title":"KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: A phase I and pharmacokinetic study","volume":"10","author":"Schrijvers","year":"1999","journal-title":"Anticancer Drugs"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1225_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:21Z","timestamp":1787067441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1225_16"}},"subtitle":["Case series"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1225_16","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}